JCP Editors

Recent research has shown which immuno-agent to be effective with limited toxicity in advanced soft-tissue and bone sarcoma?
A recent study showed that after performing next-generation sequencing of non-small cell lung cancer gene panels, actionable mutations were identifiable in 65% of cases with available targeted therapeutic options.
A recent comparative study examined predictors of discharge location for patients with advanced cancer and assessed the relationship between discharge location and survival.
Twenty-four-month event-free survival may be a surrogate for overall survival in patients with peripheral T-cell lymphoma, according to a recent study.
The US Food and Drug Administration has approved the supplemental New Drug Application for alectinib as a first-line treatment for patients with a specific type of lung cancer.
The US Food and Drug Administration has approved a new blood cancer therapy for adult patients who are positive for a genetic mutation.
A recent study assessed whether neoadjuvant chemotherapy is superior to primary debulking surgery with regard to mortality and quality of life for patients with advanced epithelial ovarian cancer.
A recent study confirmed the most cost-effective treatment option in heavily pretreated patients with relapsed or refractory multiple myeloma.
A recent study calls for new standards for hospital ED staff to manage certain conditions for older patients with cancer in observation status, and to reserve hospital resources for other patients.
A recent survey found that approximately 33% of patients with breast cancer forego their physician-recommended adjuvant therapies due to distrust in medical institutions and insurers.